FASN and non-small cell lung carcinoma: Consistently, in patients with resectable non-small-cell lung cancer (NSCLC), higher FASN activity in the cancer tissues (relative to the adjacent non-cancer lung tissue) was associated with adverse outcomes and predicts shorter patient survival (18).